Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Saturday.
A number of other research analysts have also weighed in on HKMPF. Jefferies Group lowered Hikma Pharmaceuticals from a “hold” rating to an “underperform” rating in a research report on Wednesday. Zacks Investment Research upgraded Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold”.
Shares of Hikma Pharmaceuticals (OTCMKTS HKMPF) traded down $1.04 during trading on Friday, hitting $14.06. The stock had a trading volume of 600 shares, compared to its average volume of 17. Hikma Pharmaceuticals has a 52-week low of $12.40 and a 52-week high of $27.50.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.